220 related articles for article (PubMed ID: 791234)
1. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
Graybiel A; Knepton J; Shaw J
Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
[TBL] [Abstract][Full Text] [Related]
2. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
Graybiel A; Cramer DB; Wood CD
Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
[TBL] [Abstract][Full Text] [Related]
3. Human assay of antimotion sickness drugs.
Graybiel A; Wood CD; Knepton J; Hoche JP; Perkins GF
Aviat Space Environ Med; 1975 Sep; 46(9):1107-18. PubMed ID: 1100039
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of antimotion sickness drugs.
Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
[TBL] [Abstract][Full Text] [Related]
5. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
Graybiel A; Cramer DB; Wood CD
Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological interventions for motion sickness: cardiovascular effects.
Sunahara FA; Farewell J; Mintz L; Johnson WH
Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
[TBL] [Abstract][Full Text] [Related]
7. Effect of transdermally administered scopolamine in preventing motion sickness.
McCauley ME; Royal JW; Shaw JE; Schmitt LG
Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
[TBL] [Abstract][Full Text] [Related]
8. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
[TBL] [Abstract][Full Text] [Related]
9. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
Noy S; Shapira S; Zilbiger A; Ribak J
Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
[TBL] [Abstract][Full Text] [Related]
10. Side effects of antimotion sickness drugs.
Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
[TBL] [Abstract][Full Text] [Related]
11. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
[TBL] [Abstract][Full Text] [Related]
12. Investigation of anti-motion sickness drugs in the squirrel monkey.
Cheung BS; Money KE; Kohl RL; Kinter LB
J Clin Pharmacol; 1992 Feb; 32(2):163-75. PubMed ID: 1613127
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antimotion sickness drug side effects on performance.
Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
[TBL] [Abstract][Full Text] [Related]
15. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the effectiveness of drugs for prevention of motion sickness].
Galle RR; Gusakova GA; Sabaev VV; Galle NN
Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982
[No Abstract] [Full Text] [Related]
17. Evaluation of a new antinauseant drug for the prevention of motion sickness.
Graybiel A; Knepton J
Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
[No Abstract] [Full Text] [Related]
18. Prevention and treatment of space sickness in shuttle-orbiter missions.
Graybiel A
Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and duration of intramuscular antimotion sickness medications.
Wood CD; Stewart JJ; Wood MJ; Mims M
J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161
[TBL] [Abstract][Full Text] [Related]
20. Transdermal scopolamine in the prevention of motion sickness at sea.
Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
